Neurocrine Biosciences shares drop as trial failures may ‘stunt momentum,’ analysts say

Company will halt development of experimental depression treatment
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.